Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Renal Drug Excretion: Tubular Reabsorption01:25

Renal Drug Excretion: Tubular Reabsorption

Tubular reabsorption, a process occurring post-glomerular filtration of drugs in the renal tubule, is a critical determinant of drug half-life. During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. This...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Renal Drug Excretion: Tubular Secretion01:28

Renal Drug Excretion: Tubular Secretion

Active tubular secretion is a robust, energy-demanding process that utilizes carrier systems to transport drugs into renal tubules. The active renal secretion systems include the organic anion transporter (OAT) for weak acids and the organic cation transporter (OCT) for weak bases. Structurally similar drugs can compete for the same transporter, potentially leading to drug accumulation and toxicity. However, this principle can be exploited therapeutically. One example is probenecid (Probalan),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Mitochondrial Aconitase-2 Mediates the Transcription of Nuclear-Encoded Electron Transport Chain Genes in Fission Yeast.

Journal of microbiology (Seoul, Korea)·2024
Same author

Inverted U-Shaped Relationship between Obesity Parameters and Bone Mineral Density in Korean Adolescents.

Journal of clinical medicine·2023
Same author

Variations in aragonite saturation state and its controlling factors in the South Yellow Sea in spring and autumn.

Marine pollution bulletin·2023
Same author

Overseas Air Medical Repatriation of National Soccer Players Infected With Coronavirus Disease 2019 and Contacted Staff From Austria to South Korea.

Air medical journal·2021
Same author

Effect of Hemodialysis on Peripapillary Choroidal Thickness Measured by Swept-Source Optical Coherence Tomography.

Journal of glaucoma·2020
Same author

New oral spherical carbon adsorbent effectively reduces serum indoxyl sulfate levels in moderate to advanced chronic kidney disease patients: a multicenter, prospective, open-label study.

BMC nephrology·2020

Related Experiment Video

Updated: May 23, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

V2 receptor antagonist; tolvaptan.

Joo-Hark Yi1, Hyun-Jong Shin, Ho-Jung Kim

  • 1Renal Division, Department of Internal Medicine, Hanyang University Guri Hospital, Guri, Korea.

Electrolyte & Blood Pressure : E & BP
|March 23, 2012
PubMed
Summary

Tolvaptan effectively treats hyponatremia, a common electrolyte disorder, by increasing free water excretion. This vasopressin receptor antagonist improves serum sodium levels in patients with heart failure, cirrhosis, or SIADH.

Keywords:
arginine vasopressin receptorshyponatremiatolvaptan

More Related Videos

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Related Experiment Videos

Last Updated: May 23, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine
06:40

Combined Infusion and Stimulation with Fast-Scan Cyclic Voltammetry (CIS-FSCV) to Assess Ventral Tegmental Area Receptor Regulation of Phasic Dopamine

Published on: April 23, 2020

A Novel Method: Super-selective Adrenal Venous Sampling
06:08

A Novel Method: Super-selective Adrenal Venous Sampling

Published on: September 15, 2017

Area of Science:

  • Nephrology
  • Endocrinology
  • Internal Medicine

Background:

  • Hyponatremia is the most frequent electrolyte disturbance in hospitalized individuals.
  • It is associated with increased morbidity and mortality in conditions like heart failure, liver cirrhosis, and neurological diseases.
  • Optimal hyponatremia management is challenging due to diverse causes and pathophysiologies.

Purpose of the Study:

  • To evaluate the efficacy and safety of vasopressin receptor antagonists, specifically Tolvaptan, in managing hyponatremia.
  • To highlight Tolvaptan's aquaretic effect for selective free water excretion.

Main Methods:

  • Review of clinical evidence on Tolvaptan's use in euvolemic or hypervolemic hyponatremia.
  • Assessment of Tolvaptan's impact on serum sodium levels in patients with heart failure, cirrhosis, or SIADH.
  • Evaluation of Tolvaptan's safety and tolerability for chronic hyponatremia treatment.

Main Results:

  • Tolvaptan significantly improves serum sodium levels in patients with euvolemic or hypervolemic hyponatremia.
  • Beneficial effects on serum sodium were observed across mild and marked hyponatremia.
  • Tolvaptan demonstrates acceptable safety and tolerability for long-term use.

Conclusions:

  • Vasopressin receptor antagonists like Tolvaptan offer an effective treatment strategy for hyponatremia.
  • Tolvaptan provides a targeted approach to increase free water excretion and correct serum sodium levels.
  • Tolvaptan is a safe and tolerable option for managing chronic hyponatremia associated with various underlying conditions.